Home/Filings/4/0001213900-22-048763
4//SEC Filing

Vivo Capital Fund VIII, L.P. 4

Accession 0001213900-22-048763

CIK 0001831363other

Filed

Aug 15, 8:00 PM ET

Accepted

Aug 16, 8:44 PM ET

Size

21.3 KB

Accession

0001213900-22-048763

Insider Transaction Report

Form 4
Period: 2022-08-12
Transactions
  • Purchase

    Common Stock

    2022-08-12$2.98/sh+1,123,021$3,346,6031,480,374 total(indirect: By Vivo Opportunity Fund Holdings, L.P.)
  • Purchase

    Pre-funded Warrants (right to buy)

    2022-08-16$2.42/sh+1,500,000$3,629,8501,500,000 total(indirect: By: Vivo Opportunity Fund Holdings, L.P.)
    Exercise: $0.00Common Stock (1,500,000 underlying)
  • Purchase

    Common Stock

    2022-08-16$2.42/sh+1,500,000$3,630,0002,981,592 total(indirect: By: Vivo Opportunity Fund Holdings, L.P.)
  • Purchase

    Common Stock

    2022-08-15$2.99/sh+1,218$3,6421,481,592 total(indirect: By: Vivo Opportunity Fund Holdings, L.P.)
Holdings
  • Common Stock

    (indirect: By: Vivo Capital Fund VIII, L.P.)
    2,036,557
  • Common Stock

    (indirect: By: Vivo Capital Surplus Fund VIII, L.P.)
    281,223
Transactions
  • Purchase

    Pre-funded Warrants (right to buy)

    2022-08-16$2.42/sh+1,500,000$3,629,8501,500,000 total(indirect: By: Vivo Opportunity Fund Holdings, L.P.)
    Exercise: $0.00Common Stock (1,500,000 underlying)
  • Purchase

    Common Stock

    2022-08-12$2.98/sh+1,123,021$3,346,6031,480,374 total(indirect: By Vivo Opportunity Fund Holdings, L.P.)
  • Purchase

    Common Stock

    2022-08-15$2.99/sh+1,218$3,6421,481,592 total(indirect: By: Vivo Opportunity Fund Holdings, L.P.)
  • Purchase

    Common Stock

    2022-08-16$2.42/sh+1,500,000$3,630,0002,981,592 total(indirect: By: Vivo Opportunity Fund Holdings, L.P.)
Holdings
  • Common Stock

    (indirect: By: Vivo Capital Surplus Fund VIII, L.P.)
    281,223
  • Common Stock

    (indirect: By: Vivo Capital Fund VIII, L.P.)
    2,036,557
Transactions
  • Purchase

    Common Stock

    2022-08-15$2.99/sh+1,218$3,6421,481,592 total(indirect: By: Vivo Opportunity Fund Holdings, L.P.)
  • Purchase

    Common Stock

    2022-08-12$2.98/sh+1,123,021$3,346,6031,480,374 total(indirect: By Vivo Opportunity Fund Holdings, L.P.)
  • Purchase

    Common Stock

    2022-08-16$2.42/sh+1,500,000$3,630,0002,981,592 total(indirect: By: Vivo Opportunity Fund Holdings, L.P.)
  • Purchase

    Pre-funded Warrants (right to buy)

    2022-08-16$2.42/sh+1,500,000$3,629,8501,500,000 total(indirect: By: Vivo Opportunity Fund Holdings, L.P.)
    Exercise: $0.00Common Stock (1,500,000 underlying)
Holdings
  • Common Stock

    (indirect: By: Vivo Capital Fund VIII, L.P.)
    2,036,557
  • Common Stock

    (indirect: By: Vivo Capital Surplus Fund VIII, L.P.)
    281,223
Transactions
  • Purchase

    Common Stock

    2022-08-12$2.98/sh+1,123,021$3,346,6031,480,374 total(indirect: By Vivo Opportunity Fund Holdings, L.P.)
  • Purchase

    Common Stock

    2022-08-16$2.42/sh+1,500,000$3,630,0002,981,592 total(indirect: By: Vivo Opportunity Fund Holdings, L.P.)
  • Purchase

    Common Stock

    2022-08-15$2.99/sh+1,218$3,6421,481,592 total(indirect: By: Vivo Opportunity Fund Holdings, L.P.)
  • Purchase

    Pre-funded Warrants (right to buy)

    2022-08-16$2.42/sh+1,500,000$3,629,8501,500,000 total(indirect: By: Vivo Opportunity Fund Holdings, L.P.)
    Exercise: $0.00Common Stock (1,500,000 underlying)
Holdings
  • Common Stock

    (indirect: By: Vivo Capital Surplus Fund VIII, L.P.)
    281,223
  • Common Stock

    (indirect: By: Vivo Capital Fund VIII, L.P.)
    2,036,557
Transactions
  • Purchase

    Common Stock

    2022-08-12$2.98/sh+1,123,021$3,346,6031,480,374 total(indirect: By Vivo Opportunity Fund Holdings, L.P.)
  • Purchase

    Common Stock

    2022-08-15$2.99/sh+1,218$3,6421,481,592 total(indirect: By: Vivo Opportunity Fund Holdings, L.P.)
  • Purchase

    Pre-funded Warrants (right to buy)

    2022-08-16$2.42/sh+1,500,000$3,629,8501,500,000 total(indirect: By: Vivo Opportunity Fund Holdings, L.P.)
    Exercise: $0.00Common Stock (1,500,000 underlying)
  • Purchase

    Common Stock

    2022-08-16$2.42/sh+1,500,000$3,630,0002,981,592 total(indirect: By: Vivo Opportunity Fund Holdings, L.P.)
Holdings
  • Common Stock

    (indirect: By: Vivo Capital Surplus Fund VIII, L.P.)
    281,223
  • Common Stock

    (indirect: By: Vivo Capital Fund VIII, L.P.)
    2,036,557
Footnotes (5)
  • [F1]Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
  • [F2]The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $2.83 to $3.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (2) to this Form 4.
  • [F3]The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $2.96 to $3.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4.
  • [F4]The reporting person acquired 1,500,000 shares of Common Stock at $2.42 per share and 1,500,000 pre-funded warrants at $2.41990 per warrant in an underwritten offering.
  • [F5]The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 4.99% of the outstanding shares of Common Stock of the Issuer.

Issuer

Terns Pharmaceuticals, Inc.

CIK 0001831363

Entity typeother

Related Parties

1
  • filerCIK 0001618788

Filing Metadata

Form type
4
Filed
Aug 15, 8:00 PM ET
Accepted
Aug 16, 8:44 PM ET
Size
21.3 KB